These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

463 related items for PubMed ID: 18479468

  • 1. Time of the day for 11beta-HSD1 inhibition plays a role in improving glucose homeostasis in DIO mice.
    Véniant MM, Hale C, Komorowski R, Chen MM, St Jean DJ, Fotsch C, Wang M.
    Diabetes Obes Metab; 2009 Feb; 11(2):109-17. PubMed ID: 18479468
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
    Wamil M, Seckl JR.
    Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
    [Abstract] [Full Text] [Related]

  • 3. Sub-chronic administration of the 11beta-HSD1 inhibitor, carbenoxolone, improves glucose tolerance and insulin sensitivity in mice with diet-induced obesity.
    Taylor A, Irwin N, McKillop AM, Flatt PR, Gault VA.
    Biol Chem; 2008 Apr; 389(4):441-5. PubMed ID: 18225986
    [Abstract] [Full Text] [Related]

  • 4. Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats.
    Livingstone DE, Walker BR.
    J Pharmacol Exp Ther; 2003 Apr; 305(1):167-72. PubMed ID: 12649365
    [Abstract] [Full Text] [Related]

  • 5. Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
    Lloyd DJ, Helmering J, Cordover D, Bowsman M, Chen M, Hale C, Fordstrom P, Zhou M, Wang M, Kaufman SA, Véniant MM.
    Diabetes Obes Metab; 2009 Jul; 11(7):688-99. PubMed ID: 19527482
    [Abstract] [Full Text] [Related]

  • 6. Anti-diabetic and anti-adipogenic effects of a novel selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor in the diet-induced obese mice.
    Park JS, Rhee SD, Jung WH, Kang NS, Kim HY, Kang SK, Ahn JH, Kim KY.
    Eur J Pharmacol; 2012 Sep 15; 691(1-3):19-27. PubMed ID: 22760069
    [Abstract] [Full Text] [Related]

  • 7. Dehydroepiandrosterone inhibits the amplification of glucocorticoid action in adipose tissue.
    Apostolova G, Schweizer RA, Balazs Z, Kostadinova RM, Odermatt A.
    Am J Physiol Endocrinol Metab; 2005 May 15; 288(5):E957-64. PubMed ID: 15613680
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological evaluation of adipose dysfunction via 11β-hydroxysteroid dehydrogenase type 1 in the development of diabetes in diet-induced obese mice with cortisone pellet implantation.
    Akiyama N, Akiyama Y, Kato H, Kuroda T, Ono T, Imagawa K, Asakura K, Shinosaki T, Murayama T, Hanasaki K.
    J Pharmacol Exp Ther; 2014 Apr 15; 349(1):66-74. PubMed ID: 24511146
    [Abstract] [Full Text] [Related]

  • 9. Localization and glucocorticoid regulation of 11beta-hydroxysteroid dehydrogenase type 1 mRNA in the male mouse forebrain.
    Pelletier G, Luu-The V, Li S, Bujold G, Labrie F.
    Neuroscience; 2007 Mar 02; 145(1):110-5. PubMed ID: 17207581
    [Abstract] [Full Text] [Related]

  • 10. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
    Stimson RH, Walker BR.
    Minerva Endocrinol; 2007 Sep 02; 32(3):141-59. PubMed ID: 17912154
    [Abstract] [Full Text] [Related]

  • 11. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective 11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and demonstration of pharmacodynamic effects in C57Bl/6 mice.
    Johansson L, Fotsch C, Bartberger MD, Castro VM, Chen M, Emery M, Gustafsson S, Hale C, Hickman D, Homan E, Jordan SR, Komorowski R, Li A, McRae K, Moniz G, Matsumoto G, Orihuela C, Palm G, Veniant M, Wang M, Williams M, Zhang J.
    J Med Chem; 2008 May 22; 51(10):2933-43. PubMed ID: 18419108
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of 11β-hydroxysteroid dehydrogenase 1 by carbenoxolone affects glucose homeostasis and obesity in db/db mice.
    Dhanesha N, Joharapurkar A, Shah G, Kshirsagar S, Dhote V, Sharma A, Jain M.
    Clin Exp Pharmacol Physiol; 2012 Jan 22; 39(1):69-77. PubMed ID: 22060140
    [Abstract] [Full Text] [Related]

  • 13. Overexpression of 11β-hydroxysteroid dehydrogenase type 1 in visceral adipose tissue and portal hypercortisolism in non-alcoholic fatty liver disease.
    Candia R, Riquelme A, Baudrand R, Carvajal CA, Morales M, Solís N, Pizarro M, Escalona A, Carrasco G, Boza C, Pérez G, Padilla O, Cerda J, Fardella CE, Arrese M.
    Liver Int; 2012 Mar 22; 32(3):392-9. PubMed ID: 22136330
    [Abstract] [Full Text] [Related]

  • 14. 11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice.
    Hermanowski-Vosatka A, Balkovec JM, Cheng K, Chen HY, Hernandez M, Koo GC, Le Grand CB, Li Z, Metzger JM, Mundt SS, Noonan H, Nunes CN, Olson SH, Pikounis B, Ren N, Robertson N, Schaeffer JM, Shah K, Springer MS, Strack AM, Strowski M, Wu K, Wu T, Xiao J, Zhang BB, Wright SD, Thieringer R.
    J Exp Med; 2005 Aug 15; 202(4):517-27. PubMed ID: 16103409
    [Abstract] [Full Text] [Related]

  • 15. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons.
    Hult M, Shafqat N, Elleby B, Mitschke D, Svensson S, Forsgren M, Barf T, Vallgårda J, Abrahmsen L, Oppermann U.
    Mol Cell Endocrinol; 2006 Mar 27; 248(1-2):26-33. PubMed ID: 16431016
    [Abstract] [Full Text] [Related]

  • 16. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
    Nuotio-Antar AM, Hachey DL, Hasty AH.
    Am J Physiol Endocrinol Metab; 2007 Dec 27; 293(6):E1517-28. PubMed ID: 17878220
    [Abstract] [Full Text] [Related]

  • 17. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
    Wang M.
    Handb Exp Pharmacol; 2011 Dec 27; (203):127-46. PubMed ID: 21484570
    [Abstract] [Full Text] [Related]

  • 18. Comparative enzymology of 11beta-hydroxysteroid dehydrogenase type 1 from six species.
    Arampatzis S, Kadereit B, Schuster D, Balazs Z, Schweizer RA, Frey FJ, Langer T, Odermatt A.
    J Mol Endocrinol; 2005 Aug 27; 35(1):89-101. PubMed ID: 16087724
    [Abstract] [Full Text] [Related]

  • 19. Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice.
    Alberts P, Engblom L, Edling N, Forsgren M, Klingström G, Larsson C, Rönquist-Nii Y, Ohman B, Abrahmsén L.
    Diabetologia; 2002 Nov 27; 45(11):1528-32. PubMed ID: 12436336
    [Abstract] [Full Text] [Related]

  • 20. Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor.
    Hale C, Véniant M, Wang Z, Chen M, McCormick J, Cupples R, Hickman D, Min X, Sudom A, Xu H, Matsumoto G, Fotsch C, St Jean DJ, Wang M.
    Chem Biol Drug Des; 2008 Jan 27; 71(1):36-44. PubMed ID: 18069989
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.